Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Neoadjuvant Therapy in OSCC
NCT07137858Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in oral squamous cell carcinoma (OSCC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07137858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137858.